Companies › Chiome Bioscience
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CBA-1535 T cell engager (bispecific antibody engaging 5T4 and CD3) | TRAC, 5T4 | Phase 1 | Solid Tumors | Dec 2026 |
| CBA-1205 anti-DLK1 monoclonal antibody | DLK1 | Phase 1 | Solid Tumors | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07016997 | CBA-1535 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT06636435 | CBA-1205 | Phase 1 | Solid Tumors | Oncology | Jun 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.